H. M. Osman And M. Tuncbilek, "Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusion-positive, Recurrent or Advanced Solid Tumors," CURRENT MEDICINAL CHEMISTRY , vol.29, no.15, pp.2602-2616, 2022
Osman, H. M. And Tuncbilek, M. 2022. Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusion-positive, Recurrent or Advanced Solid Tumors. CURRENT MEDICINAL CHEMISTRY , vol.29, no.15 , 2602-2616.
Osman, H. M., & Tuncbilek, M., (2022). Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusion-positive, Recurrent or Advanced Solid Tumors. CURRENT MEDICINAL CHEMISTRY , vol.29, no.15, 2602-2616.
Osman, Hind, And MERAL TUNÇBİLEK. "Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusion-positive, Recurrent or Advanced Solid Tumors," CURRENT MEDICINAL CHEMISTRY , vol.29, no.15, 2602-2616, 2022
Osman, Hind M. And Tuncbilek, MERAL. "Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusion-positive, Recurrent or Advanced Solid Tumors." CURRENT MEDICINAL CHEMISTRY , vol.29, no.15, pp.2602-2616, 2022
Osman, H. M. And Tuncbilek, M. (2022) . "Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusion-positive, Recurrent or Advanced Solid Tumors." CURRENT MEDICINAL CHEMISTRY , vol.29, no.15, pp.2602-2616.
@article{article, author={Hind M. Osman And author={MERAL TUNÇBİLEK}, title={Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusion-positive, Recurrent or Advanced Solid Tumors}, journal={CURRENT MEDICINAL CHEMISTRY}, year=2022, pages={2602-2616} }